Our team at UN&UP recently attended the 2023 International BIO Conference in Boston. We were honored to have been chosen by the NIH to present our groundbreaking TheraLode technology, which utilizes magneto-thrombolysis.

During the conference, we engaged in fruitful discussions with numerous VCs and strategics. We had over 30 meetings, all of which were incredibly beneficial to our goal of advancing toward early clinical trials. This therapy has the potential to improve the standards of care for thrombolysis significantly.

Our attendance at the conference was made possible by the NIH NINDS Phase 2 SBIR award R44NS122604.